Among 3 minimally invasive technologies (percutaneous coronary intervention (PCI), left atrial appendage closure (LAAC) and transcatheter aortic valve replacement (TAVR)), PCI is the most commonly utilized method, and is used by 82% of cardiologists according to a study conducted by iData Research at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting in 2018. In contrast to PCI, the other two methods have limited penetration in the global cardiologist community with 31% having performed transcatheter aortic valve replacement (TAVR) and 18% having performed left atrial appendage closure (LAAC).
In reference to iData’s study, TAVR was found to be performed most commonly in the U.S. and Europe, and it’s also being used in surgeries in Latin America. However, this technology is still relatively new for those in the Asia Pacific region, where only 16% of specialists have experience with TAVR procedures.
The more experience that cardiologists have, the higher the chances are that they have performed a TAVR procedure in 2018. Specifically, 50% of those with more than 31 years in practice predict they will use or try this technique in 2019. Those who are working at Academic Medical Centers perform TAVR more often than some other locations, and 35% of them actively want to use this technique. However, cardiologists in community hospitals and private hospitals are not as confident in trying TAVR procedures.
There are strict requirements for physicians performing TAVR procedures, including extensive experience and advanced medical equipment necessary to perform it successfully. Thus, it is easy to understand why people in academic facilities have a greater chance of familiarizing themselves with TAVR procedures. The average respondent is expected to perform 53% more TAVR procedures in 2019 than in 2018. This increase is forecast to occur in all segments, and for cardiologists handling a high volume of patients per week, they see those numbers increase more significantly than other cardiologists with a lower weekly patient volume.
More than 50% of TAVR procedures in 2019 are expected to use cerebral protection systems, up from 27% in 2018. Cardiologists in all regions expect to increase the number of TAVR procedures with cerebral protection, but the strongest increase is predicted to take place in Europe with a procedure volume increase expected of up to 73.3% over 2018. 31.9% of cardiologists believe that cerebral protection works best in soft plaques and/or severe calcification patient categories in the ascending aorta and/or aortic arch, followed by the severely calcified aortic valve category. Not many cardiologists believe that cerebral protection can be effective for those patients with severe strokes.
Physicians in Europe and Latin America were found to prefer Boston Scientific’s Sentinel Cerebral Protection System over competing products. Boston Scientific acquired Sentinel from Claret Medical in July 2018 for a purchase price of $220 million U.S.
To Learn Why Cardiologists Say this…
The full survey conducted across 213 cardiologists globally is available for purchase by iData Research. This report outlines this TAVR research in detail, among similar data for PCI and LAAC procedures.
Click here to speak to an iData representative today to bring this data and insight to the forefront of your product and marketing strategies.
